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SUMMARY – Erectile dysfunction (ED) is a highly prevalent disorder among renal transplant 
recipients. Vitamin D defi ciency (VDD) has been associated with several ED risk factors but only 
recently directly linked to ED. We conducted a study to investigate whether vitamin D serum levels 
were associated with the presence and severity of ED in 40 male patients that underwent deceased 
donor kidney transplantation (TX) from 2001 to 2013. Blood samples were collected on two season-
ally distinct occasions and 25(OH)D concentration was assessed by radioimmunoassay. A 5-item 
version of the International Index of Erectile Function (IIEF-5) was used for ED evaluation and 
group stratifi cation. We found comparable rates of ED (75%) and VDD (42.5%-62.5%) as in previ-
ously published studies. Serum levels of 25(OH)D did not diff er between patients with and those 
without ED on both measurements (p=0.656 and p=0.914, respectively), or when comparing diff erent 
ED severity groups. Duration of renal replacement therapy before TX and graft duration until analy-
sis were longer in patients with ED (p=0.022 and p=0.05, respectively), but with the results being 
nonsignifi cant on logistic regression. In conclusion, we found no association of 25(OH)D concentra-
tion with the presence and severity of ED in renal transplant recipients. So far, there are no similar 
published data.
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Introduction
Erectile dysfunction (ED) is defi ned as persistent 
inability of a man to achieve and/or maintain penile 
erection suffi  cient for sexual activity. It is a highly 
prevalent disorder worldwide, with the reported preva-
lence of 69.2% of men, varying according to diff erent 
methodological approaches in the published studies, 
and increasing with age1-3. ED was historically consid-
ered a benign condition, however, not only does it im-
pair the quality of life but also carries an increased risk 
of impending cardiovascular disease (CVD)4 because 
of the common pathological mechanism of endothe-
lial dysfunction (END).
Vitamin D has recently been shown to have a wide 
variety of extraskeletal eff ects, with pathways linked to 
cancer, autoimmune disorders and CVD. By changing 
the expression of 200 to 2000 genes that have vitamin 
D response elements, these eff ects include inhibition 
of angiogenesis and cellular proliferation, stimulation 
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of apoptosis and terminal diff erentiation5. A random-
ized, double-blind study6 has revealed that vitamin D 
supplementation indeed changed the expression of 
genes linked to CVD, which have been associated with 
vitamin D defi ciency (VDD). VDD is defi ned as se-
rum circulating 25-hydroxyvitamin D (25(OH)D) 
concentration below 20 ng/mL, vitamin D insuffi  cien-
cy as 25(OH)D of 21-29 ng/mL, and suffi  ciency above 
30 ng/mL7.
Vitamin D defi ciency has previously been associ-
ated with several ED risk factors such as hypertension, 
diabetes mellitus (DM) and atherosclerosis, which all 
cause endothelial impairment of penile vasculature, as 
well as with some nonvascular disorders linked both to 
ED and VDD8. One recent study9 found a direct link 
between the presence of ED and VDD.
Th e prevalence of ED in chronic kidney disease 
(CKD) patients is reported to be about 80%10, which is 
higher than in general population. Albeit the etiology 
of ED is usually multifactorial, there are numerous 
CKD specifi c factors that predispose these patients to 
ED, including hormonal abnormalities, END, comor-
bidities, polypragmasy, and depression. Th ere are no 
recent or conclusive data on VDD and ED in CKD 
population, but a report11 from 1977 implied that 
treatment with vitamin D supplements reduced ED 
severity in dialysis patients. In a setting after renal 
transplantation (TX), erectile function seems to im-
prove compared to pre-transplant dialysis period10, al-
though ED remains frequent companion of renal 
transplant recipients. Th ere are recent eff orts in focus-
ing not only on patient and graft survival but also on 
the life quality after renal TX, where ED plays an im-
portant role12.
Since data on VDD and ED in CKD population 
are sparse, in this study we set to determine vitamin D 
status of renal transplant recipients on two seasonally 
distinct measurements and to investigate whether vita-
min D serum levels are associated with the presence 
and severity of ED. To our knowledge, there are no 
similar data published so far.
Patients and Methods
Th e study was conducted at the Department of 
Urology and Department of Dialysis, Osijek Univer-
sity Hospital Center, where transplant recipients have 
their regular checkup. Th e study was approved by the 
Ethics Committee of the Osijek University Hospital 
Center, in accordance with the 2000 Declaration of 
Helsinki and 2008 Declaration of Istanbul. After hav-
ing obtained their written informed consent, 40 male 
patients having undergone deceased donor kidney TX 
from 2001 to 2013 were enrolled in the study. Patient 
characteristics were obtained by an in-house question-
naire, while clinical data were collected from patient 
charts and medical records. Blood samples were col-
lected from cubital vein on two seasonally distinct oc-
casions: fi rst sample in summer 2013 ( June through 
August) and second sample in winter 2013/2014 (De-
cember through April), with body height and weight 
measurements taken during physical examination on 
both occasions.
Assessment of vitamin D serum concentration was 
performed with DIAsource radioimmunoassay and 
immunoradiometric assay kit was used for parathyroid 
hormone (PTH) measurement (DIAsource Immuno-
Assays S.A., Louvain-la-Neuve, Belgium), following 
the manufacturer’s instructions.
A simplifi ed 5-item version of the International 
Index of Erectile Function (IIEF-5) was used as a di-
agnostic tool for ED evaluation13 and to further divide 
study subjects into diff erent ED categories. According 
to the IIEF-5 score, the patients were categorized as 
no ED (ED 0; score 22-25), ED 1 (score 17-21), ED 
2 (score 12-16), ED 3 (score 8-11) and ED 4 group 
(score ≤7). Th e groups were then compared according 
to serum levels of 25(OH)D, complete blood count, 
hemoglobin, PTH, fasting blood glucose, creatinine, 
high-sensitivity C-reactive protein (hs-CRP), choles-
terol and triglycerides per body mass index (BMI), du-
ration of renal replacement therapy (RRT) before TX, 
and kidney graft duration until analysis.
Statistical analysis was performed with the SPSS 
statistical program (version 15.0, SPSS Inc., Chicago, 
IL, USA). All data were reported as median (range 
from minimum to maximum), unless noted otherwise. 
Diff erence between two independent samples was cal-
culated with Mann-Whitney test, and among more 
than two independent samples with Kruskal-Wallis 
test, while Mann-Whitney test was used for post-hoc 
analysis. Wilcoxon signed-rank test was used for re-
lated samples and Fisher exact test for categorical data. 
Correlations were assessed using Kendall’s t-B coeffi  -
cient and multivariate analysis with Hosmer-Leme-
show test. A two-sided p-value of <0.05 was consid-
ered statistically signifi cant.
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Results
Demographic characteristics of 40 study partici-
pants having undergone kidney TX from June 2001 to 
May 2013 are shown in Table 1. Glomerulonephritis 
was the primary cause of end-stage renal disease 
(ESRD) in most of the subjects and 90% of the pa-
tients were fi rst-time kidney transplant recipients. As 
expected, 77.5% of the patients were taking three or 
more drugs besides immunosuppressants, while seven 
patients received vitamin D supplements.
When stratifi ed according to the IIEF-5 score, ten 
patients had no ED (ED 0), 20 patients were classifi ed 
as ED 1, seven patients as ED 2, and three patients as 
ED 4; there were no ED 3 patients. Median age of all 
patients was 52 (range 29-66) years, with no signifi -
cant between-group diff erence (p=0.32). On the fi rst 
(summer) measurement of 25(OH)D, 42.5% of pa-
tients had VDD, 30% were vitamin D insuffi  cient, and 
27.5% had suffi  cient levels of 25(OH)D. On the sec-
ond measurement (winter), 62.5% had VDD, 17.5% 
had insuffi  ciency, and only 20% of patients were vita-
min D suffi  cient. Th e levels of 25(OH)D did not diff er 
between the two measurements (p=0.737). Th ere was 
no statistically signifi cant between-group diff erence as 
compared according to serum levels of 25(OH)D, 
PTH, hemoglobin, fasting blood glucose, creatinine, 
hs-CRP, cholesterol, triglycerides, BMI, duration of 
RRT before TX, and graft duration until analysis.
Th en we compared the studied variables between 
patients without ED and those with any degree of ED 
(Table 2). Serum levels of 25(OH)D and other serum 
parameters analyzed yielded no statistically signifi cant 
diff erences either. However, duration of RRT before 
TX and graft duration until analysis were shorter in 
ED 0 group (p=0.022 and p=0.05, respectively). Logis-
tic regression analysis of the two mentioned parame-
ters plus age at the time of the study (p=0.083 in uni-
variate analysis) revealed no between-group diff erence 
(p=0.152, p=0.479 and p=0.334, respectively).
When stratifying study subjects according to 
25(OH)D cutoff  of 20 ng/mL (Table 3), there was no 
diff erence in the IIEF-5 score, duration of RRT before 
TX and graft duration until analysis on either mea-
surement. However, the fi rst (summer) measurement 
showed lower HDL cholesterol, red blood cell and he-
moglobin concentrations in VDD group (p=0.007, 
p=0.013 and p=0.009, respectively). VDD group had 
lower HDL cholesterol on second (winter) measure-
ment (p=0.016) again and higher PTH levels com-
pared to non-VDD group (p=0.009). Logistic regres-
sion for the fi rst measurement HDL, hemoglobin and 
serum glucose (p=0.097 in univariate analysis) and for 
the second measurement HDL, hemoglobin (p=0.065 
in univariate analysis) and PTH revealed the parame-
Table 1. Demographic characteristics of study population 
(N=40)
n (%)
Primary cause of ESRD
Glomerulonephritis 19 (47.5)
Interstitial nephritis 8 (20)
DM 6 (15)
ADPKD 5 (12.5)

















Beta blockers 25 (62.5)
ACE inhibitors/ARBs 23 (57.5)
Loop diuretics 10 (25)
Vitamin D supplements 7 (17.5)
Erythropoietin 5 (12.5)
Bisphosphonates 4 (10)
ESRD = end-stage renal disease; ADPKD = autosomal dominant 
polycystic kidney disease; TAC = tacrolimus; CsA = cyclosporin; 
mTOR = mammalian target of rapamycin; TX = renal transplanta-
tion; DM = diabetes mellitus; AMI = acute myocardial infarction; 
PAD = peripheral arterial disease; CVI = cerebrovascular insult; 
ACE = angiotensin-converting enzyme; ARBs = angiotensin re-
ceptor blockers
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ters to pose no signifi cant risk (p=0.06, p=0.075, 
p=0.141, p=0.094, p=0.363 and p=0.059, respectively). 
Oral vitamin D supplementation therapy had no im-
pact on the distribution of 25(OH)D levels between 
the groups (p=0.463 and p=0.326 for the fi rst and sec-
ond measurement, respectively).
Discussion
In the current study, we measured serum 25(OH)D 
concentration on two occasions in renal transplant 
 recipients and found no association of vitamin D  status 
with the presence and severity of ED. Along with the 
recent abundant evidence for extraskeletal eff ects of 
vitamin D, there has been an increasing number of 
 papers stressing its role in CVD, autoimmune and 
chronic infl ammatory disorders, as well as in cancer. 
A review by Hossein-Nezhad and Holick5 empha-
sizes that a great deal of numerous vitamin D aff ected 
genes have a role in diff erent tumor pathways, cellular 
cycle regulation and immuno-infl ammatory modula-
tion.
Table 2. Comparison of non-ED (ED 0) versus patients with any degree of ED 
(both summer and winter measurements)
ED 0 ED 1-4 p-value
n 10 30
Age (years) 47.5 (30-61) 54 (29-66) 0.083
IIEF-5 score 24.5 (22-25) 17 (5-21) <0.001
RRT before TX (months) 21 (9-95) 47.5 (8-108) 0.022
Graft duration until 
analysis (months)














































































All data reported as median (range from minimum to maximum); p calculated using Mann-Whitney test; 
Aupper value indicates summer and lower value winter measurement; ED = erectile dysfunction; IIEF-5 = 
International Index of Erectile Function questionnaire; RRT = renal replacement therapy; TX = renal trans-
plantation; BMI = body mass index; Hgb = hemoglobin; hs-CRP = high-sensitivity C-reactive protein; HDL 
= high-density lipoprotein; LDL = low-density lipoprotein; PTH = parathyroid hormone
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Vitamin D defi ciency has already been linked to 
classic CVD risk factors, such as infl ammation in vas-
cular endothelium, DM and hypertension, which all 
are shared ED risk factors causing END8. Recently, it 
was demonstrated that a signifi cant proportion of ED 
patients had VDD, again with END as a plausible un-
derlying pathologic mechanism9. CKD, an indepen-
dent risk factor for CVD, with its concomitant meta-
bolic diseases and END is a particularly good setting 
for ED to occur10, a fi nding supported by observation-
al studies. In addition, CKD patients are predisposed 
to ED because of hormonal abnormalities, anemia and 
usage of multiple drugs such as beta blockers and some 
diuretics, which can worsen the erectile function. Fur-
thermore, even after successful kidney TX, where im-
provement of erectile function is expected14, there are 
vascular factors to be taken into consideration that 
may have an impact on postoperative ED occurrence. 
End-to-end arterial anastomosis with the internal iliac 
artery has previously been shown to reduce cavernosal 
arterial fl ow15, but recently similar eff ect was also found 
for end-to-side external iliac artery anastomosis16.
Vitamin D defi ciency in CKD population has been 
extensively studied but never linked to ED. Th ere are 
numerous reports of high VDD prevalence among 
kidney transplant recipients17-19, but the high-level evi-
dence for its exact impact on major outcomes (glomer-
ular fi ltration rate, acute rejection, chronic allograft 
nephropathy, proteinuria and graft loss) is still lacking, 
although a systematic review is underway20. Apart 
from traditional VDD risk factors5 (age, race, female 
gender, geographic latitude, altitude, time of day, win-
ter season, air pollution, and obesity) and preventive 
reduced sun exposure in transplant recipients, there is 
also evidence that 25(OH)D levels are inversely asso-
ciated with the usage of calcineurin inhibitors as im-
Table 3. Comparison of 25(OH)D defi cient versus non-defi cient patients (both summer and winter measurements)
Summer measurement Winter measurement
25(OH)D >20 ng/mL <20 ng/mL p >20 ng/mL <20 ng/mL p
n 23 17 15 25
Age (years) 52 (29-66) 54 (30-66) 0.426 54 (31-64) 49 (29-66) 0.401
IIEF-5 score 19 (7-25) 18 (5-25) 0.711 18 (7-24) 19 (5-25) 0.280
RRT before TX 
(months)
48 (8-105) 29 (9-108) 0.194 46 (8-103) 44 (9-108) 0.748
Graft duration 
(months)
33 (1-145) 22 (4-106) 0.298 28 (1-145) 34 (4-137) 0.716
BMI 25 (22.5-33.4) 25.8 (21.5-37.8) 0.345 26.2 (22.2-34) 25.7 (22.6-36.1) 0.791
25(OH)D (ng/mL) 29.49 (20.71-67.3) 9.11 (6.03-20.27) <0.001 35 (21.35-64.17) 16.2 (3.4-20.3) <0.001
RBC (x1012/L) 4.9 (3.44-6.19) 4.11 (3.26- 5.04) 0.013 5 (4.17-6.71) 4.65 (2.89-6.2) 0.083
Hgb (g/L) 139 (98-169) 118 (88-150) 0.009 143 (115-151) 133 (80-165) 0.065
Blood glucose 
(mmol/L)
5.3 (3.7-7.2) 5.8 (4.8-19.7) 0.097 5.6 (4.8-10.4) 5.4 (4.8-7.9) 0.433
hs-CRP (mg/L) 2.13 (0.22-27.84) 1.51 (0.21-17.06) 0.795 2.81 (0.71-9.78) 1.85 (0.18-68.62) 0.356
Cholesterol 
(mmol/L)
5.305 (2.9-8.1) 4.94 (2.6-7.8) 0.380 5.66 (3.8-8.5) 5.335 (2.6-7.9) 0.212
HDL (mmol/L) 1.39 (0.8-2.6) 1.09 (0.8-1.5) 0.007 1.45 (0.9-2.7) 1.16 (0.8-1.9) 0.016
LDL (mmol/L) 3.56 (2-5.6) 3.25 (1.5-5.5) 0.865 3.82 (2.4-5.9) 3.65 (1.6-5.7) 0.557
Triglycerides 
(mmol/L)
1.675 (0.7-7.3) 2.13 (0.8-6.3) 0.149 1.42 (0.9-3.6) 2.02 (1.1-7) 0.209
PTH (pg/mL) 109 (36.5-379) 113 (33.9-894) 0.924 43 (13.6-162) 126 (21-735) 0.009
All data reported as median (range from minimum to maximum); p calculated using Mann-Whitney test; IIEF-5 = International Index of 
Erectile Function questionnaire; RRT = renal replacement therapy; TX = renal transplantation; BMI = body mass index; RBC = red blood 
cell; Hgb = hemoglobin; hs-CRP = high-sensitivity C-reactive protein; HDL = high-density lipoprotein; LDL = low-density lipoprotein; 
PTH = parathyroid hormone
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munosuppressants17. In a recent study, Yildirim et al.21 
found signifi cantly lower vitamin D levels in renal 
transplant recipients with END compared to patients 
with normal endothelial function, and conclude that 
VDD is associated with END in that population. To 
our knowledge, the only reference to VDD impact on 
ED in CKD patients is found in an article published 
in 1977, reporting on improvement of erectile function 
in dialysis patients after treatment with vitamin D 
supplements11.
In our study, we found similar rates of VDD as in 
previously published studies17-19. On the summer and 
winter measurements of 25(OH)D, VDD was present 
in 42.5% and 62.5% of patients, insuffi  ciency in 30% 
and 17.5%, while 27.5% and 20% of patients were vi-
tamin D suffi  cient. As expected, the fi nding of a high-
er percent of VDD in winter season was due to sea-
sonal variations in cutaneous production of vitamin D. 
Th e Croatia’s geographic latitude is between 42° i 46° 
north of the equator, where there is little if any vitamin 
D produced in skin during winter months, regardless 
of the amount of sun exposure5,22. However, the distri-
bution of 25(OH)D levels did not diff er between the 
two measurements (summer median of 22.05 ng/mL 
versus winter median of 19.05 ng/mL; p=0.737). Th is 
could be explained by general sun avoiding in kidney 
transplant patients, according to their nephrologist 
recommendation or vitamin D supplementation in 
some of them. Th e fi nding of lower red blood cell and 
hemoglobin concentrations in VDD patients is in line 
with the published data on VDD association with 
anemia in CKD patients. Although the exact mecha-
nism is unknown, VDD may impair erythropoiesis via 
immune activation within the bone marrow23.
Out of 40 study patients, only 10 (25%) had no ED 
(ED 0 group), 20 patients had mild (ED 1) and seven 
patients mild to moderate ED (ED 2), while three pa-
tients had severe ED (ED 4 group). Th e high presence 
of ED among our renal transplant recipients is in line 
with earlier reports of 42% to 78% prevalence in this 
population12,24-27. Th e levels of 25(OH)D and PTH, as 
well as other study parameters on both measurements 
did not diff er among ED groups. We then compared 
ED 0 and other ED categories (Table 2) and found no 
diff erence in 25(OH)D levels between patients with 
and without ED. Time on RRT before TX and graft 
duration until analysis were signifi cantly shorter in 
non-ED group, but on logistic regression the results 
proved to be nonsignifi cant. Th e association of both 
shorter RRT time before TX and recently performed 
TX with better erectile function could be explained by 
less time on pre-transplant dialysis and better renal 
function in the early postoperative months.
On stratifying study patients according to 25(OH)
D cutoff  of 20 ng/mL, we found the distribution of 
IIEF-5 score to be similar and again nonsignifi cant for 
both measurements, which recapitulated our fi nding 
of no vitamin D status linkage to ED in the current 
study. Th e explanation for this could be based on the 
multifactorial ED etiology in a population already pre-
disposed to ED, so that pinpointing VDD as an exclu-
sive ED cause is somewhat improbable. Also, radioim-
munoassay was a method used for 25(OH)D measure-
ment and with liquid chromatography-tandem mass 
spectrometry (LC-MS/MS), which is the gold stan-
dard for evaluating 25(OH)D status5 but currently un-
available to us, reassessment with a larger number of 
study subjects is needed. As our research was a cross-
sectional observational study, future interventional 
studies with vitamin D supplementation could pre-
sumably shed more light on its impact on ED occur-
rence and severity.
In conclusion, we found no association between vi-
tamin D serum concentration and the presence and 
severity of ED in renal transplant recipients. To date, 
there are no similar published data linking VDD and 
ED in CKD and renal transplant populations. High 
rates of VDD and ED found in this population should 
not be considered as a quality-of-life matter only be-
cause of the possible and/or proven eff ects on patient 
general health via END and CVD.
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Sažetak
NEPOVEZANOST SERUMSKOG STATUSA VITAMINA D I EREKTILNE DISFUNKCIJE 
U PRIMATELJA BUBREŽNOG PRESATKA
B. Sudarević, I. Begić, D. Šimunović, H. Kuveždić, V. Šerić i L. Zibar
Erektilna disfunkcija (ED) je poremećaj visoke učestalosti u bolesnika nakon transplantacije bubrega. Defi cijencija vita-
mina D (VDD) je već ranije povezana s nekoliko rizičnih čimbenika za ED, ali je tek nedavno dovedena u izravnu vezu s ED. 
U predmetnom smo istraživanju ispitali je li serumska vrijednost vitamina D povezana s prisutnošću i jačinom izraženosti 
ED u 40 muških ispitanika u kojih je kadaverična transplantacija bubrega (TX) učinjena od 2001. do 2013. godine. Serumsko 
uzorkovanje je učinjeno u dva sezonski različita razdoblja, uz mjerenje koncentracije vitamina D radioimuno testom. Upitnik 
International Index of Erectile Function (IIEF-5) korišten je za stratifi kaciju bolesnika s obzirom na jačinu ED. Pronašli smo 
usporedivu učestalost ED (75%) i VDD (42,5%-62,5%) kao u dosad objavljenim istraživanjima. Ni u jednom mjerenju nije 
utvrđena razlika u serumskim vrijednostima 25(OH)D između ispitanika s ED i bez nje (p=0,656 i p=0,914), kao ni među 
ispitanicima s različito izraženom ED. Trajanje bubrežne nadomjesne terapije (RRT) prije TX i “trajanje” transplantata do 
analize bilo je duže za ispitanike s ED (p=0,022 odnosno p=0,05), no samo u univarijatnoj analizi. Zaključno, nismo pro našli 
povezanost između serumske razine 25(OH)D i prisutnosti te jačine izraženosti ED. Prema našim spoznajama, dosad nema 
sličnih objavljenih rezultata za navedenu populaciju bolesnika.
Ključne riječi: Vitamin D, nedostatak; Erektilna disfunkcija; Endotel, vaskularni; Bubrežna insufi cijencija, kronična; Bubreg, 
transplantacija; Hrvatska
